Bristol-Myers v. Biocraft
Bristol-Myers received a preliminary injunction prohibiting Biocraft from marketing its generic cefadroxil antibiotic on Feb. 28, Bristol announced in a same-day release. Newark Federal Court Judge Dickenson Debevoise determined that the generic product would infringe on Bristol-Myers' crystalline cefadroxil monohydrate patent, due to expire in 2002. Bristol-Myers is seeking a full trial in order to obtain a permanent injunction. Biocraft has 90 days to appeal the ruling to the U.S. Court of Appeals.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.